GSK plc GLAXF
OTC PK
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 44.98B | 44.55B | 43.93B | 43.12B | 42.05B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 44.98B | 44.55B | 43.93B | 43.12B | 42.05B |
| Cost of Revenue | 11.80B | 11.80B | 11.92B | 11.82B | 11.59B |
| Gross Profit | 33.18B | 32.75B | 32.02B | 31.30B | 30.47B |
| SG&A Expenses | 12.22B | 12.21B | 12.12B | 11.89B | 11.71B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.70B | -1.87B | -1.92B | -1.31B | -580.43M |
| Total Operating Expenses | 32.11B | 31.50B | 31.18B | 31.19B | 31.01B |
| Operating Income | 12.87B | 13.05B | 12.75B | 11.93B | 11.05B |
| Income Before Tax | 7.23B | 7.94B | 9.98B | 9.75B | 9.21B |
| Income Tax Expenses | 752.36M | 861.06M | 1.45B | 1.46B | 1.25B |
| Earnings from Continuing Operations | 6.48K | 7.08K | 8.53K | 8.29K | 7.96K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -632.03M | -593.50M | -706.26M | -755.24M | -745.63M |
| Net Income | 5.85B | 6.48B | 7.83B | 7.53B | 7.22B |
| EBIT | 12.87B | 13.05B | 12.75B | 11.93B | 11.05B |
| EBITDA | 16.20B | 16.22B | 16.45B | 16.05B | 14.84B |
| EPS Basic | 1.46 | 1.61 | 1.94 | 1.86 | 1.78 |
| Normalized Basic EPS | 1.72 | 1.76 | 1.68 | 1.55 | 1.41 |
| EPS Diluted | 1.43 | 1.59 | 1.91 | 1.83 | 1.75 |
| Normalized Diluted EPS | 1.69 | 1.74 | 1.66 | 1.52 | 1.39 |
| Average Basic Shares Outstanding | 16.07B | 16.09B | 16.14B | 16.20B | 16.27B |
| Average Diluted Shares Outstanding | 16.30B | 16.32B | 16.37B | 16.44B | 16.49B |
| Dividend Per Share | 0.93 | 0.91 | 0.90 | 0.87 | 0.84 |
| Payout Ratio | 61.91% | 55.18% | 44.43% | 44.90% | 45.82% |